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The study of Hepatitis C Virus (HCV) has beneﬁtted from the use of the Huh7 cell culture system, but
until recently there were no other widely used alternatives to this cell line. Here we render another
human hepatoma cell line, Hep3B, permissive to the complete virus life cycle by supplementation with
the liver-speciﬁc microRNA miR-122, known to aid HCV RNA accumulation. When supplemented,
Hep3B cells produce J6/JFH-1 virus titres indistinguishable from those produced by Huh7.5 cells.
Interestingly, we were able to detect and characterize miR-122-independent replication of di-cistronic
replicons in Hep3B cells. Further, we show that Argonaute-2 (Ago2) is required for miR-122-dependent
replication, but dispensable for miR-122-independent replication, conﬁrming Ago2’s role in mediating
the activity of miR-122. Thus Hep3B cells are a model system for the study of HCV, and miR-122
independent replication is a model to identify proteins involved in the function of miR-122.
& 2012 Elsevier Inc. All rights reserved.Introduction
Hepatitis C is a blood-borne viral disease that naturally infects
only humans and is prevalent worldwide. As of July 2012, the
WHO estimates that 150 million people worldwide are infected
with Hepatitis C virus (HCV) (WHO, 2012). HCV exposure leads to
chronic liver infections in an estimated 70% of individuals, and
can lead to the development of liver disease, steatosis, hepato-
cellular carcinoma, and other complications late in chronicity
(Strader et al., 2004). Unfortunately, no preventative or therapeu-
tic vaccine yet exists, and treatment options are limited. Current
standard of care involves lengthy combination therapy with
pegylated IFN-a and ribavirin. Recent approval of two new
protease inhibitors, telaprevir and boceprevir, has improved
treatment outcomes and when one or the other is added to the
cocktail, approximately 70% of genotype 1-infected patients (the
most prevalent and difﬁcult to treat) clear the infection (Myers
et al., 2012). New direct-acting antiviral drugs currently underll rights reserved.
ewan, Department of Micro-
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A. Wilson).development should further improve the effectiveness of current
treatment (Poordad and Dieterich, 2012).
A member of the Flaviviridae family, HCV is an enveloped virus
with a 9.6 kb single-stranded positive-sense RNA genome. The
uncapped 50 un-translated region (UTR) of the viral genome bears
an internal ribosomal entry site (IRES) that drives translation of
the virus’ single open reading frame as a polyprotein. The
polyprotein is co- and post-translationally cleaved by cellular
and viral proteases to produce the structural (core, E1, E2) and
non-structural (p7, NS2, NS3, NS4a and 4b, NS5a and 5b) viral
proteins. Both the 50 and 30 UTRs have signiﬁcant secondary RNA
structure that is essential for viral translation and replication
(Bartenschlager et al., 2004).
In 2005, Jopling et al. (2005, 2008) identiﬁed two binding sites
for the liver-speciﬁc microRNA, miR-122, in the 50 UTR of HCV;
miR-122 binding enhances accumulation of HCV RNA in infected
cells. MicroRNA-122 comprises about 70% of the small RNAs in
the mammalian liver, and modulates expression of mRNAs
involved in cholesterol biosynthesis, proliferation, and cell differ-
entiation (Esau et al., 2006; Lagos-Quintana et al., 2002; Lin et al.,
2008; Norman and Sarnow, 2010).
miRNA expression is often dysregulated or abolished in cancer
cells. Expression of miR-122 is typically reduced or lost in liver
cancers, but is more likely to be maintained in cases of HCV-
associated liver cancer (Coulouarn et al., 2009; Varnholt et al.,
P.A. Thibault et al. / Virology 436 (2013) 179–1901802008). Similarly, hepatocyte cell lines that were established from
liver tumors also generally lack miR-122 expression. Huh7-
derived cell lines are the only human liver cell lines known to
have signiﬁcant endogenous expression of miR-122, and these
were also the ﬁrst cell line to robustly support replication of HCV
(Jopling et al., 2005). While expression of the miRNA is consider-
ably lower in these cells than in primary human hepatocytes,
other liver cancer cell lines such as HepG2 and Hep3B cells have
undetectable levels of miR-122 and are also non-permissive for
HCV replication (Varnholt et al., 2008). This information led to the
hypothesis that miR-122 plays a role in the host cell tropism of
HCV; this hypothesis is supported by several reports. Supplemen-
tation with miR-122 of non-permissive mouse embryonic ﬁbro-
blasts (MEF), HEK (human embryonic kidney), and HepG2 and
Hep3B (human hepatoma) cells with miR-122 has rendered them
permissive for transient replication of HCV RNAs derived from the
JFH-1 isolate (Chang et al., 2008; Fukuhara et al., 2012; Kambara
et al., 2012; Lin et al., 2010; Narbus et al., 2011). HepG2
and Hep3B cells were also capable of producing HCV particles.
However, stable RNA replication of JFH-1-derived replicons
has also been demonstrated in cells that do not express miR-
122, such as murine embryonic ﬁbroblasts (MEFs), through the
use of selectable markers, suggesting that miR-122 is not essen-
tial for ongoing HCV replication (Chang et al., 2006; Uprichard
et al., 2006).
The mechanism of action of miR-122 in the HCV life cycle is
unknown. The activity of miR-122 in the replication of HCV is
non-canonical, since it binds to the 50 end of the viral genome and
requires annealing of nucleotides outside of the miR-122 seed
sequence (Machlin et al., 2011; Shimakami et al., 2012b). Micro-
RNAs normally bind to the 30 ends of cellular mRNAs in a
sequence speciﬁc manner, within a complex with other proteins
such as Argonaute-2 (Ago2) to form a RISC (RNA-inducedFig. 1. Replication of sub-genomic (SGR) HCV in Hep3B cells. (A) Components of ‘‘SGR,’’
isolate. The replicon lacks the structural genes required to form particles, but has all th
un-translated regions (UTRs). The ﬁreﬂy luciferase reporter gene is driven by the HCV IR
human hepatoma cell lines were evaluated by TaqMan qRT-PCR. Levels are determined
Huh7.5 cells are derived from Huh7 cells; HepG2 and Hep3B cells are of separate linea
WT; or replication-incompetent, GND), and miRNA. Fireﬂy luciferase expression was e
luciferase enzyme extracted from cell lysates. All data shown is the average of thre
represent standard error. (D) Total cellular RNA from (C) was collected three days post-e
three experiments. GAPDH is shown as a loading control. HCV (8.4 kb) refers to the sisilencing complex), and subsequently reduce mRNA translation
and stability (Du and Zamore, 2005).
Recent evidence suggests that miR-122 binding to the HCV
genome stabilizes the viral RNA (Shimakami et al., 2012b).
However, miR-122 has also been reported to enhance translation
and augment RNA accumulation (Henke et al., 2008; Jangra et al.,
2010a, 2010b; Jopling et al., 2005; Machlin et al., 2011; Roberts
et al., 2011; Villanueva et al., 2010). It is possible that the primary
function of miR-122 is to stabilize viral RNA, and that the
observed inﬂuences of miR-122 on HCV translation and replica-
tion stem frommiR-122 modulation of HCV RNA stability, but this
remains to be conﬁrmed. To further tease these activities apart,
researchers have begun to examine the cellular factors involved
in miR-122-mediated enhancement of HCV RNA accumulation,
the most obvious of which are the proteins in the microRNA
biogenesis pathway and proteins that comprise the RISC. Thus
far, research has shown that Dicer and TRBP, proteins involved
in the biogenesis of microRNAs, are required for processing of
miR-122, and that Ago2 is required for miR-122 stabilization of
HCV RNA, for efﬁcient HCV RNA accumulation, and for miR-122
stimulation of HCV translation (Machlin et al., 2011; Shimakami
et al., 2012a, 2012b; Wilson et al., 2011; Zhang et al., 2012).
We, and others, have hypothesized that miR-122 is a limiting
factor in HCV tissue tropism and cell culture models, and herein
we have conﬁrmed replication of the J6/JFH-1 viral RNA in Hep3B
cells supplemented with miR-122, showing that these cells can
produce virus particles to the same titers as Huh7.5 cells.
Additionally, through use of Hep3B cells as a model system,
we have identiﬁed and characterized miR-122-independent repli-
cation of two di-cistronic HCV replicons, the sub-genomic JFH-1
replicon, and the full-genomic JFH-1 replicon. MicroRNA-122-
independent replication of HCV provides a model system in which
to investigate the roles of cellular proteins in miR-122 processes,the di-cistronic sub-genomic ﬁreﬂy luciferase reporter replicon based on the JFH-1
e necessary non-structural genes required for replication, along with the 50 and 30
ES, while viral protein expression is driven by an EMCV IRES. (B) miR-122 levels in
relative to a housekeeping small RNA, RNU6B, for comparison between cell lines.
ges. (C) Cells were electroporated with the indicated SGR replicon RNA (wild-type,
valuated at the indicated time points. RLU are a measure of light produced by the
e or more independent experiments, unless otherwise indicated, and error bars
lectroporation and evaluated by northern blot. The blot shown is representative of
ze of the SGR replicon genome.
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of miR-122. As proof of principle we evaluated the role of Ago2 in
replication of the sub-genomic replicon with and without miR-
122, and determined that Ago2 knockdown does not inﬂuence
miR-122-independent replication, but has an effect on miR-122-
dependent replication. This conﬁrms that Ago2 is involved in the
activity of miR-122 as it promotes HCV RNA accumulation.Results
Supplementation with miR-122 renders Hep3B cells permissive
to sub-genomic HCV RNA replication.
Many human hepatomas have lost the ability to express the liver-
speciﬁc miRNA, miR-122 (Coulouarn et al., 2009). Unlike commonly
used human hepatoma cell lines such as Hep3B cells and HepG2 cells,
Huh7-derived cells (such as Huh7.5) retained easily detectable levels
of miR-122 expression after transformation (Fig. 1B, Jopling et al.,
2005), and are also permissive to Hepatitis C virus replication.
Because of this, and because miR-122 has been shown to impact
HCV translation and replication, we hypothesized that miR-122 is a
limiting factor in some non-permissive cell lines, and that providing
miR-122 will render them permissive for HCV replication and virion
production. Electroporating Hep3B cells with synthetic mature miR-
122 duplexed RNA permitted high levels of replication of the sub-
genomic JFH-1 HCV replicon (SGR, depicted in Fig. 1A), as measured
by the ﬁreﬂy luciferase reporter gene in Fig. 1C, and conﬁrmed by
northern blot analysis of viral RNA accumulation (Fig. 1D).
Replication-incompetent viral RNA (SGR GND) was used to establish
basal levels of luciferase expression in the absence of replication. Both
luciferase expression and accumulation of sub-genomic RNA inFig. 2. Replication of full-length (J6/JFH-1 Rluc) HCV in Hep3B cells. (A) Representation
bears all the viral genes, is capable of producing infectious particles in cell culture, and
genes. (B) Hep3B cells were electroporated with either wild-type (WT) or replication
expression levels were measured at the indicated times post-electroporation. (C) Da
luciferase expression in the Huh7.5 cells three days post-infection indicated the prese
shown on the axis in part (B). (D) Northern blot of J6/JFH-1 RNA in Hep3B cells 3
supplemented with miR-122. HCV (10.1 kb) refers to the size of the full-length replic
electroporation were titrated for HCV focus-forming units (FFU). (F) Northern blot comp
miR-122, three days post-electroporation. Bands are quantiﬁed by densitometry, and no
þ/ standard deviation, and are presented relative to Huh7.5 cells. In all other panels
error bars represent standard error of the mean.Hep3B cells were similar to that observed in Huh7.5 cells (data not
shown). Transfection efﬁciency was determined by co-electroporation
of a Renilla mRNA and analysis of Renilla luciferase expression levels
two hours post-electroporation, and did not vary between samples
(data not shown). Cell numbers were evaluated three days post-
electroporation by WST-1 assay, and were consistent among samples
in each experiment (data not shown).Full-length HCV RNA can replicate and generate infectious virus
particles in Hep3B cells
Co-electroporation of J6/JFH-1 RNA (depicted in Fig. 2A) and
miR-122 also renders Hep3B cells permissive to replication of full-
length HCV RNA (Fig. 2B). Expression of the Renilla luciferase (Rluc)
reporter conﬁrmed replication of full length HCV RNA in Hep3B cells
when co-electroporated withmiR-122. In the absence of miR-122, the
Rluc expression pattern overlapped that of the non-replicating GNN
control (Fig. 2B, compare WTþmiControl and GNNþmiR-122).
Full-length HCV RNA accumulation by replication was conﬁrmed by
northern blot analysis (Fig. 2D). Tissue culture supernatant was
collected on Day 3 post-electroporation and analyzed for the presence
of HCV particles. When the supernatant was used to infect naı¨ve
Huh7.5 cells, luciferase expression in the newly infected cells (Fig. 2C)
indicated the presence of infectious HCV particles in the supernatant
from Hep3B cells supplemented with miR-122. Focus-forming assays
showed that infectious virus titers in the supernatant from miR-122-
supplemented Hep3B cells were similar to that from Huh7.5 cells
(Fig. 2E). Northern blot analysis of HCV RNA levels in miR-122
supplemented Hep3B cells compared with Huh7.5 cells (Fig. 2F)
indicates that at three days post-electroporation, Hep3B cells hadof ‘‘J6/JFH-1 Rluc,’’ the mono-cistronic full-length J6/JFH-1 chimeric replicon, which
has a Renilla luciferase reporter gene. The HCV IRES drives translation of all the
-incompetent (GNN) J6/JFH-1 Rluc RNA, and the indicated microRNA. Luciferase
y 3 supernatant from Hep3B cells in (B) was used to infect naı¨ve Huh7.5 cells;
nce of infectious HCV virions in the supernatant. Luciferase expression levels are
days post-electroporation, demonstrating HCV RNA replication in Hep3B cells
on genome. (E) Supernatant from both Hep3B and Huh7.5 cells three days post-
aring levels of J6/JFH-1 RNA in Huh7.5 cells, and in Hep3B cells supplemented with
rmalized to GAPDH. Percentages are an average of seven independent experiments,
, the data are presented as the average of three independent experiments and the
Fig. 3. Long-term replication of full-length HCV RNA in Hep3B cells. (A) Luciferase levels representing replication of J6/JFH-1 Rluc HCV RNA in Hep3B cells were evaluated
at the indicated time points post-electroporation. (B) Luciferase levels representing infectious HCV particles in supernatants collected from ‘wild-typeþmiR-1220 in (A).
Supernatant was collected at each time point and used to infect naive Huh7.5 cells; three days after infection, luciferase levels were analyzed to measure approximate
supernatant infectivity. (C) Relative miR-122 levels in Huh7.5 cells, un-electroporated Hep3B cells, and Hep3B cells electroporated with miR-122 collected at the indicated
times post-electroporation. miR-122 levels were determined by TaqMan qRT-PCR and normalized to RNU6B. Data represent the average of three independent experiments
and bars represent standard error.
Fig. 4. Infection of Hep3B cells with full-length J6/JFH-1 HCVcc. (A) Hep3B cells were
transfected via Lipofectamine 2000 with the indicated miRNA one day before being
infected with HCVcc (J6/JFH-1 particles derived from Huh7.5 cells) or mock-infected
with media on Day 0. Luciferase was analyzed at the indicated time points to detect
infection and subsequent replication. (B) Supernatant was collected from the infected
Hep3B cells in (A) on Day 4, and was used to infect naı¨ve Huh7.5 cell. Three days later,
luciferase expression, in the same axis as in (A), was analyzed in the infected Huh7.5
cells to detect infection. Data are the average of three independent experiments and
error bars represent standard error.
P.A. Thibault et al. / Virology 436 (2013) 179–190182similar levels of HCV RNA accumulation as that observed in Huh7.5
cells.
Replication levels and virus particle production coincide with
miR-122 levels in Hep3B cells
To determine how long Hep3B cells can support full-length viral
replication when supplemented with synthetic mature miR-122
duplex RNA, we monitored HCV replication via luciferase expression,
until none was detectable. By 15 days post-electroporation, little to
no replication or infectious virus particle production was apparent in
Hep3B cells (Fig. 3A and B). We evaluated miR-122 levels by qRT-PCR
at the same time points and determined that HCV replication
paralleled the levels of exogenously supplied miR-122 (Fig. 3C). At
Day 6, miR-122 levels were similar to that found in Huh7.5 cells, and
by Day 9, miR-122 levels had dropped to 30% of miR-122 levels in
Huh7.5 cells. The drop in miR-122 levels appears to correspond to the
decline in HCV replication and particle production (as measured by
luciferase). Thus, viral RNA replication and particle production coin-
cide with miR-122 levels in Hep3B cells.
Hep3B cells supplemented with miR-122 are permissive for HCV
infection
Finally, we examined whether Hep3B cells can also support
virus entry, and thus recapitulate a full round of infection when
supplemented with miR-122. One day before infection, were
transfected via Lipofectamine 2000 with either miR-122 or a
control microRNA, and on day 0, were infected with J6/JFH-1
HCVcc (virus derived from Huh7.5 cells). Fig. 4A show luciferase
expression from the infected cells at the indicated time points
post-infection. Hep3B cells supplemented with miR-122 show
detectable luciferase expression post-infection. Furthermore, on
Day 4 post-infection, supernatant from the infected cells was
transferred to Huh7.5 cells for detection of infectious virus
particle production. As can be seen in Fig. 4B, Hep3B cells bearing
miR-122 prior to infection can carry out the viral life cycle
and produce infectious virions, but at lower levels compared to
cells electroporated with viral RNA, which suggests inefﬁcient
HCV entry into miR-122 transfected Hep3B cells. To ensure
that the original virus HCVcc used to infect the cells could notcontaminate the virus supernatants collected on Day 4, the Hep3B
cells were washed and media was changed the day following the
initial infection. Failure to detect virus in supernatant from Hep3B
cells electroporated with miControl (grey) conﬁrmed that there
was no contaminating HCVcc remaining.
Sub-genomic HCV RNA can replicate in Hep3B cells un-supplemented
with miR-122
Interestingly, luciferase expression levels in Hep3B cells electro-
porated with HCV sub-genomic RNA (without miR-122) were greater
than those of the replication-incompetent GND control (Fig. 1C,
compare WTþmiControl to GNDþmiControl). This suggested that
SGR wild-type RNA was persisting longer than non-replicating RNA,
P.A. Thibault et al. / Virology 436 (2013) 179–190 183even in the absence of miR-122 supplementation. RNA levels from
SGR in the absence of miR-122 were not initially detected by
northern blot (Fig. 1D), but above-background luciferase expression
was consistently seen. In addition, luciferase levels increased after
Day 1 post-electroporation, indicating that SGR RNA replicated in
Hep3B cells even without miR-122 supplementation. We ruled out
the possibility that the miControl synthetic RNA impacted sub-
genomic replication by electroporating viral RNA with no accompa-
nying microRNA into Hep3B cells, and found similar luciferase
production as when miControl was provided (data not shown). We
hypothesized that HCV RNA replication could be due to either low
levels of active miR-122 within Hep3B cells, or alternatively that sub-
genomic RNA can replicate in Hep3B cells independent of the activity
of miR-122.Hep3B cells lack functional endogenous miR-122
To rule out possible contribution of endogenous miR-122 on un-
supplemented SGR replication in Hep3B cells, we analyzed the levels
and activity of miR-122 in Hep3B cells. Real-time PCR analysis of
miR-122 levels in Hep3B cells had indicated that Hep3B cells do not
express consistently detectable amounts of miR-122 (Fig. 1B). To
analyze for functional miR-122 in Hep3B cells we assayed for miR-
122 suppression activity. In the assay, miR-122 suppression activity
was monitored by using two plasmids (Fig. 5A); one bears a ﬁreﬂy
luciferase gene (Fluc) with HCV-derived miR-122 binding sites in the
3’ UTR to measure miR-122 suppression, and the other bears a Renilla
luciferase gene (Rluc) to control for transfection efﬁciency (Jopling
et al., 2008; Machlin et al., 2011). If miR-122 is present in the co-
electroporated cells, then expression of ﬁreﬂy luciferase will be
reduced via the miRNA suppression pathway. If this is the case, then
a miR-122 antagonist should relieve the suppression. When theFig. 5. Hep3B cells lack functional miR-122. (A) Reporters used in miRNA functional ass
sites in its 30 UTR; binding of miR-122 to these sites suppresses translation of the ﬁreﬂy
a transfection control. (B) Hep3B cells were electroporated with the indicated miRNA or
express the mRNAs shown in (B). One day post-transfection, cells were assayed for
luciferase levels. Data are the average of three independent experiments and are sho
standard error. (C) Hep3B cells were electroporated with SGR RNA and the indicated
dilutions are shown relative to 60.0 pmol miControl. miR-122 dilutions are 1:1 (60.0 p
replicating luciferase levels.reporter plasmids were electroporated alone or with the miR-122
antagonist (a-miR-122), similar Fluc:Rluc ratios were observed,
indicating no active miR-122 in Hep3B cells (Fig. 5B). In control
experiments, the miR-122 antagonist was conﬁrmed to be active
since electroporation of synthetic miR-122 enhanced suppression
activity, and the miR-122 antagonist completely abolished this
enhancement (Fig. 5B, miR-122, and a-miR-122þmiR-122).
We also titrated amounts of miR-122 that can affect SGR by
electroporating Hep3B cells with SGR RNA and 10-fold dilutions of
miR-122 (Fig. 5C). Addition of 60 pmol of miR-122 appeared to
saturate the systems involved in replication, as addition of greater
amounts of miR-122 (5X, 300 pmol, and 10X, 600 pmol) did not
further increase replication (data not shown). A 10-fold dilution of
miR-122 (6.0 pmol) led to approximately 10-fold less luciferase
expression on Day 3 post-electroporation, and when we supplemen-
ted with 0.6 pmol (a hundred-fold dilution) of miR-122 we saw a
reduction in replication to levels no different than miControl-
supplemented SGR RNA. Thus, a hundred-fold dilution (0.6 pmol) of
miR-122 is below the threshold level required to augment HCV RNA
accumulation. This dilution of miR-122 is easily and consistently
detectable by qRT-PCR (Fig. 3C, and data not shown), and so we
concluded that amounts of miR-122 not consistently detectable by
qRT-PCR also do not affect HCV RNA accumulation, although we
cannot rule out the existence of undetectable levels of miR-122 in
Hep3B cells.HCV replication in Hep3B cells in the absence of miR-122
is not affected by a miR-122 antagonist
To conﬁrm that miR-122 un-supplemented sub-genomic HCV
RNA replication in Hep3B cells was not dependent on miR-122,
we tested whether it was affected by miR-122 antagonism. Inays. Top: pLUC-1222 encodes a ﬁreﬂy luciferase mRNA bearing miR-122 binding
luciferase reporter. Bottom: pRL-TK encodes a Renilla luciferase mRNA to be used as
a-miR-122. Two days later, cells were transfected with two reporter plasmids that
both luciferase reporters’ expression levels, and data was normalized to Renilla
wn as fold suppression compared to miControl by each miRNA. Bars represent
miRNA dilutions. Luciferase was measured three days post-electroporation, and
mol), 1:10 (6.0 pmol) and 1:100 (0.6 pmol). The GND mutant demonstrates non-
Fig. 6. MicroRNA-122-independent replication of sub-genomic HCV. (A) Left: Diagram of SGR construct. Right: Schematic of the miR-122 binding sites in the HCV 50 UTR.
Blue letters show miR-122 and black letters are HCV RNA. Bold indicates miR-122 seed sequences, while other complementary sequences between HCV and miR-122 are
shown as aligned bases. The green arrows and bases indicate the p3 mutations in both seed sequences on the HCV genome (C to G), and the complementary changes found
in the microRNA miR-122/p3 (G to C). (B) Hep3B cells were electroporated with SGR RNA and the indicated microRNAs and/or miRNA antagonists (a-miR-122 and a-
Control). Luciferase was assayed at the indicated time points. GND is the replication-incompetent mutant of SGR as in Fig. 1C. (C) Hep3B cells were electroporated with p3
SGR RNA, which bears a mutation in position 3 of the miR-122 binding sites S1 and S2 as depicted in (A), and otherwise treated as in (B). (D) RNA collected from Hep3B
cells three days post-electroporation was evaluated by northern blot to detect miR-122-dependent (miR-122) and miR-122-independent (miControl) replication. The top
panel is overexposed in order to detect miR-122-independent replication. (E) Huh7.5 cells were electroporated as in (B). (F) Huh7.5 cells were electroporated as in (C). (G)
RNA was collected from Huh7.5 cells and evaluated as in (D). Luciferase data are the average of three independent experiments; bars represent standard error. Blots are
representative of two independent experiments. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
P.A. Thibault et al. / Virology 436 (2013) 179–190184transient HCV replication assays, un-supplemented sub-genomic
RNA replication was unaffected by the addition of the miR-122
antagonist (Fig. 6B, compare a-miR-122 to miControl and a-Con)
or a mutant miRNA (miR-122/p3), while miR-122-supplemented
sub-genomic RNA replication was reduced to un-supplemented
levels by the antagonist (Fig. 6B, compare miR-122 and miR-
122þa-Con with miR-122þa-122). RNA harvested on Day 3
following electroporation was evaluated by northern blot in
Fig. 6D, and both miR-122-dependent (miR-122) and miR-122-
independent (miControl) HCV RNA accumulation was detectableupon overexposure of the blot. Thus, sub-genomic RNA can
replicate independent of miR-122 to low levels in Hep3B cells.
Replication of p3 SGR RNA in Hep3B and Huh7.5 cells is not affected
by miR-122 or a-miR-122
If un-supplemented HCV replication in Hep3B cells is independent
of miR-122, then sub-genomic constructs that cannot bind to
endogenous miR-122 should also be capable of replication. To test
this hypothesis we generated sub-genomic constructs having various
P.A. Thibault et al. / Virology 436 (2013) 179–190 185point mutations in both miR-122 binding sites (S1 and S2) in the 50
UTR of the viral genome (Fig. 6A). We and others have shown that
point mutations in the miR-122 binding sites prevent interaction
with miR-122, and miR-122-mediated enhancement of HCV re-
plication, and that introducing complementary mutations into an
exogenously-provided miR-122 can restore this interaction, and
restore replication of HCV (Henke et al., 2008; Jangra et al., 2010b;
Machlin et al., 2011; Wilson et al., 2011). We ﬁrst tested for miR-122-
independent replication of a ‘p34’ sub-genomic RNA. The p34 mutant
bears mutations at positions 3 and 4 of both miR-122 binding sites in
the 5’ UTR and has been used by our lab and others (Jopling et al.,
2005; Wilson et al., 2011). When we evaluated the p34 sub-genomic
construct in Hep3B cells there was no indication of miR-122-
independent replication (data not shown). However, even upon
supplementation with a complementary miRNA, miR-122/p34, repli-
cation of the mutant could not be supplemented to wild-type levels
(Wilson et al., 2011). Surmising that since these RNAs could not be
fully complemented, they may be structurally ﬂawed, we then
evaluated two other constructs that each bore a single C to G point
mutation in both miR-122 binding sites, one at position 5 of the miR-
122 seed sequence (p5) and one at position 3 (p3). The p5 SGR
construct did not demonstrate replication without microRNA supple-
mentation (data not shown), but the p3 construct did (Fig. 6C), and
replicated in Hep3B cells to levels similar to that of the wild-type
construct (compare Fig. 6B – miControl to Fig. 6C – miControl).
In addition, the p3 SGR was unresponsive to exogenously provided
miR-122 (Fig. 6C, compare miR-122 to miControl), and miR-122
antagonist (Fig. 6C, compare miControl to a-miR-122; a-Control also
had no effect – data not shown) and could be complemented to near-
wild-type levels by an exogenously provided miRNA, miR-122/p3,
which bears a complementary sequence to the mutated constructFig. 7. Replication of the di-cistronic full-genome replicon (FGR) in Hep3B cells. (A)
replicon which contains structural genes that permit infectious particle production; it
wild-type (WT) or replication-incompetent (GNN) FGR RNA and the indicated micro
Supernatants from cells in (B) were collected at Day 4 post-electroporation, and were u
axis as in (B), were evaluated in the Huh7.5 cells as an indication of the presence of inf
supernatants derived from WTþmiControl electroporations; the solid black bar is the su
the subset of supernatants that showed detectable virion production. Data are the avera
error of the mean.(compare Fig. 6B – miR-122 to Fig. 6C – miR-122/p3). Because the
mutated miRNA did not affect the wild-type replicon (Fig. 6B, miR-
122/p3), and because the mutated replicon was not impacted by
wild-type miR-122 nor its antagonist (Fig. 6C, miR-122 and a-miR-
122), we conﬁrmed that the p3 mutation successfully abolished the
effects of miR-122 binding on the replicon. This further conﬁrmsmiR-
122-independent replication of HCV SGR RNA.
To ensure that miR-122-independent replication is not spe-
ciﬁc to some factor present only in Hep3B cells, we also
examined miR-122-independent replication of SGR RNA in
Huh7.5 cells. By use of a-miR-122 to antagonize the endogenous
miR-122 in Huh7.5 cells, we were able to reduce replication of
sub-genomic HCV RNA to levels similar to the miR-122-
independent replication we observed in Hep3B cells (Fig. 6E, a-
miR-122; compare with Fig. 6B, miControl). To substantiate miR-
122-independent replication in Huh7.5 cells, we analyzed repli-
cation of the p3 SGR construct in Huh7.5 cells (Fig. 6F). In Huh7.5
cells, p3 SGR replication was unaffected by the miR-122 antago-
nist (Fig. 6F, compare miControl and a-miR-122; a-Control had
no effect on p3 SGR replication – data not shown), conﬁrming
miR-122-independent replication. The p3 SGR construct still
responded to the complementary microRNA miR-122/p3. Eval-
uating Day 3 RNA from these experiments by northern blot
(Fig. 6G), miR-122-dependent (‘‘SGR WT’’ – SGR WTþmiControl)
and miR-122-independent (‘‘p3 SGR’’ – p3 SGRþmiControl) RNA
accumulation can both be detected upon overexposure of the
blot. Huh7 cells, the parent cells to the Huh7.5 line, also
supported miR-122-independent replication of p3 SGR (data
not shown). Thus, we have detected unselected miR-122-
independent replication of sub-genomic HCV RNA in three cell
lines, and have veriﬁed that a mutation in the miR-122 bindingDiagram representation of ‘‘FGR,’’ the di-cistronic full-genomic ﬁreﬂy luciferase
is otherwise identical to the SGR. (B) Hep3B cells were electroporated with FGR
RNA, and luciferase expression was measured at the indicated time points. (C)
sed to infect Huh7.5 cells. Three days after infection, luciferase levels, on the same
ectious virus particles produced from Hep3B cells. Note the ﬁrst two bars are both
bset of supernatants that showed no virion production, while the checkered bar is
ge of more than three independent experiments, and error bars represent standard
Fig. 8. Ago2 is not required for miR-122-independent replication of sub-genomic
HCV. (A) Hep3B cells were initially electroporated with either siAgo2 or siControl
on Day3; on Day 0, cells were electroporated again with the same siRNA, p3
SGR, and the indicated microRNA, along with a control Renilla mRNA. Luciferase
was assayed at the indicated time-points post-second electroporation (Day 0) to
detect RNA replication. (B) Hep3B cells were treated as in (A), but were
electroporated with SGR WT and the indicated miRNA. (C) Huh7.5 cells were
treated as in (A); SGR RNA was used to represent miR-122-dependent replication,
and p3 RNA was used to represent miR-122-independent replication. Data
represent the average of three or more independent experiments and bars
represent standard deviation.
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wild-type miR-122.
miR-122-independent replication of a full length di-cistronic
replicon RNA
The miR-122-independent replication of HCV SGR RNA in
Hep3B cells was not echoed by the J6/JFH-1 construct. Luciferase
expression levels from full-length HCV RNA electroporated with-
out miR-122 were indistinguishable from those of the non-
replicative GNN control (compare Figs. 1C and 2A, WTþmiControl
to GNN or GND). Thus we hypothesized that miR-122-
independent replication may occur because of the di-cistronic
nature of the sub-genomic replicon. Alternatively, the increased
length of the J6/JFH-1 genome could have impeded miR-122-
independent replication. In order to test both of these hypotheses,
we evaluated the replication of the full-genomic replicon (FGR) in
Hep3B cells. FGR is depicted in Fig. 7A, and is a di-cistronic
replicon RNA similar to SGR in that it contains an EMCV IRES that
drives translation of the viral proteins, but is considerably longer
since it also encodes the entire HCV polyprotein, including the
viral structural proteins. Thus, if the di-cistronic nature of the SGR
replicon facilitates miR-122-independent replication of viral RNA,
then the FGR replicon should also replicate independently of
exogenous miR-122. However, if the genome length of the J6/JFH-
1 replicon is hindering miR-122-independent replication, FGR
bears a longer sequence and should also exhibit no miR-122-
independent replication.
Our data indicates that FGR replicons can replicate indepen-
dent of miR-122 since when we electroporated FGR RNA with a
control miRNA we saw higher luciferase expression than was
observed with the replication-incompetent mutant (Fig. 7B,
WTþmiControl vs. GNN), particularly at later time points. How-
ever, luciferase levels were very low. Thus, this construct does not
appear to replicate as efﬁciently as either the SGR or J6/JFH-1
constructs in Hep3B and Huh7.5 cells (compare Fig. 7A with
Figs. 1C and 2A; and data not shown). Evaluation of supernatant
from Day 4 post-electroporation in Fig. 7C shows limited produc-
tion of infectious virus particles from miR-122-supplemented
cells. We periodically observed production of infectious virus
particles from miR-122-independent replication of FGR RNA in
Hep3B cells (checkered bar), but we do not see this in every
experiment. Thus, we believe that miR-122 un-supplemented FGR
replication in Hep3B cells can produce virus particles, but at very
low levels. These results, however, suggest that the presence of a
second IRES in the SGR and FGR replicons permits detectable
replication of the viral RNA in the absence of miR-122.
Argonaute-2 is not required for miR-122-independent replication
of sub-genomic HCV RNA
We and others have shown that Argonaute-2 (Ago2), a key
player in the microRNA suppression pathway, is required for the
role that miR-122 plays in translation and stability of HCV RNA
(Roberts et al., 2011; Shimakami et al., 2012a, 2012b; Wilson
et al., 2011). Ago2 has also been implicated in the mechanism of
miR-122 augmentation of HCV RNA accumulation through the
use of Ago2 siRNA knockdown, but these assays could not rule out
the possibility that Ago2 affected HCV replication through indir-
ect modulation of other cellular functions (Wilson et al., 2011).
To test the hypothesis that Ago2 promotes HCV replication due to
its role in mediating the activity of miR-122, we assessed the
inﬂuence of Ago2 knockdown on miR-122-independent SGR
replication in Hep3B and Huh7.5 cells (Fig. 8). In Hep3B cells,
Ago2 knockdown had no effect on miR-122/p3-independent
replication of the p3 SGR and the wild-type SGR (Fig. 8A and B,
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Ago2 knockdown severely hampered the ability of miR-122/p3 to
enhance p3 SGR luciferase expression (Fig. 8A, compare siAgo2 –
miR-122/p3 to siControl – miR-122/p3, and Fig. 8B, compare
siAgo2 – miR-122 to siControl – miR-122). Thus, the inﬂuence of
Ago2 knockdown on HCV replication is primarily via modulation
of miR-122 activity. Evaluation of cell numbers conﬁrmed that
cell survival had no impact on our luciferase results, while we
achieved 64% Ago2 mRNA knockdown as measured by qRT-PCR in
both series of experiments (Supplementary Fig. S2A and B). We
saw similar results in Huh7.5 cells. MicroRNA-122-independent
replication of p3 SGR was unaffected by Ago2 knockdown (Fig. 8C,
compare siControl – p3 to siAgo2 – p3), and miR-122-dependent
replication of wild-type SGR RNA was reduced by Ago2 knock-
down (compare siControl – SGR to siAgo2 – SGR). That Ago2
knockdown had a less severe effect on miR-122 dependent replica-
tion in Huh7.5 cells than in Hep3B cells may have been due to less
efﬁcient Ago2 knockdown, 51%, in these cells. Huh7.5 cell numbers
were also not affected by multiple electroporation (Supplementary
Fig. S2C). Thus, while Ago2 plays a critical role in miR-122-
mediated enhancement of HCV RNA accumulation, we show here
that its presence or absence does not appear to impact miR-122-
independent replication of HCV, which suggests that the disruption
of Ago2 activity outside of its role in supporting miR-122 does not
signiﬁcantly affect HCV replication following siRNA knockdown.Discussion
We have demonstrated that Hep3B cells are a valuable model
system for studying Hepatitis C Virus. Hep3B cells can be rendered
permissive for robust replication of sub-genomic (SGR), full-
genomic (FGR), and full-length (J6/JFH-1) replicons by supplemen-
tation with the liver-speciﬁc microRNA, miR-122. Supplementa-
tion with miR-122 allows us to recapitulate the complete virus life
cycle in Hep3B cells, from infection to production of new infec-
tious virus particles, although HCV entry was inefﬁcient in our
experiments. Because Hep3B cells lack endogenous miR-122, we
were also able to identify miR-122-independent replication of
sub-genomic (SGR) and full-genomic (FGR) di-cistronic replicons.
This enabled us to generate a sub-genomic mutant virus that can
replicate independently of miR-122 in both Hep3B cells and Huh7-
derived cells.
The liver-speciﬁc microRNA, miR-122, augments replication of
HCV RNA in Huh7-derived cells, and has been used to enhance
replication of stable HCV replicons in non-liver cells such as HEK
293 cells and mouse MEFs (Chang et al., 2008; Fukuhara et al.,
2012; Jopling et al., 2005; Lin et al., 2010). This led to the
development of our hypothesis that miR-122 could be used to
permit transient, unselected replication of HCV in other non-
permissive cells. In the last year, two other labs have also
published data on human liver cell lines supplemented with
miR-122 to render them permissive to HCV replication (Kambara
et al., 2012; Narbus et al., 2011). In our hands, and in the lab of Y.
Matsuura, Hep3B cells can support levels of HCV replication and
virus particle production similar to that found in Huh7-derived
cells with no selection or adaptation (Kambara et al., 2012).
Additionally, HCV RNA accumulation (Fig. 2F) and virion produc-
tion (Fig. 2E) in Hep3B cells were equivalent to that of Huh7.5 cells.
However, contrary to a previous report in which Hep3B cells stably
expressing miR-122 were highly infectable (Kambara et al., 2012),
we observed that Hep3B cells transfected with miR-122 were
much less permissive to HCV entry (Fig. 4A). Ploss et al. (2009)
and Sainz et al. (2012) found Hep3B cells to be equally as
permissive as Huh7 cells for entry by using lentiviral particles
pseudotyped with HCV envelope proteins (HCVpp) as well asHCVcc. Observations by Shimakami et al. agreed with this using
Hep3B cells stably expressing miR-122, which leads us to suspect
that transient means of providing miR-122 reduced the infect-
ability of Hep3B cells. We also observed that, Hep3B infection
efﬁciency was not improved by electroporation of miR-122 (Sup-
plementary Fig. S1); thus poor infection may have been due to
harmful effects of transfection (Fig. 4) and electroporation, or
perhaps to a different characteristic of the Hep3B cells used in
our laboratory.
High cellular levels of miR-122 coincide with efﬁcient replica-
tion of the virus (as measured by luciferase) and production of
infectious virus particles, and replication decreases as miR-122
levels decrease over time (Fig. 3). This suggests that miR-122
supports the continuing high levels of HCV RNA during the virus
life cycle. This data agrees with other reports which showed that
miR-122 antagonism reduces HCV RNA levels in stable HCV cell
lines (Jopling et al., 2005; Lee et al., 2012) and in HCV infected
chimpanzees (Lanford et al., 2010).
Interestingly, we have found that miR-122 is not essential for
replication of di-cistronic JFH-1 sub-genomic (Figs. 1C and 6) and
full-length (Fig. 7) replicons in Hep3B or Huh7.5 cells. By
determining that Hep3B cells lack functional miR-122 (Figs. 1B,
5, and 6) we have shown that the basal replication of SGR and FGR
in Figs. 1, 6, and 7 occurs independently of miR-122, and have
conﬁrmed this through use of the mutant p3 SGR. Cells harbour-
ing stably replicating HCV replicons have been established pre-
viously through antibiotic selection in cell lines that are not
known to express miR-122, which indicated the possibility of
miR-122-independent replication, but the mechanism remained a
mystery (Ali et al., 2004; Date et al., 2004; Kato et al., 2005b;
Uprichard et al., 2006). In these instances, low levels of miR-122
expression in the cells, or the evolution of adaptive mutations in
the 50 UTR, had not been eliminated. Here, we have demonstrated
transient miR-122-independent replication of HCV SGR RNA,
conﬁrming that miR-122 is not essential for replication of JFH-1
di-cistronic constructs. Thus, HCV di-cistronic replicons are cap-
able of replicating independently of miR-122, while still being
sensitive to supplementation with the microRNA.
We have validated the usefulness of a mutant miR-122 bind-
ing site replicon, the p3 SGR, to study miR-122-dependent
and -independent HCV replication. The p3 SGR replicon replicates
to levels similar to those of wild-type SGR in the absence of miR-
122, and is completely unaffected by the addition or removal of
miR-122 (Fig. 6C and E). However, when supplemented with miR-
122/p3, which bears the complementary mutation in the miRNA
sequence, replication of the p3 SGR is restored to levels that are
within three-fold of wild-type SGR in the presence of miR-122.
By supplementing the p3 SGR RNA with exogenous miR-122 in
Hep3B cells, and by using a miR-122 antagonist in Huh7.5 cells,
we conﬁrmed that it replicated entirely independent of miR-122.
Our data also suggests that a sub-genomic HCV mutant with p34
mutations at both miR-122 binding sites exhibits impaired
replication aside from lack of miR-122 binding (Wilson et al.,
2011). HCV SGR RNA carrying the p34 mutation could not
replicate independently of miR-122 (data not shown), and could
not be complemented to within a log of wild-type through use of
a complementary miR-122/p34 (Wilson et al., 2011). Interest-
ingly, both p3 and p34 mutants have been shown to reach wild-
type levels when complemented with the appropriate miRNAs in
a sub-genomic genotype 1a H77 replicon by Jopling et al., leading
us to suspect that deﬁciencies in the p34 mutant may be
particular to JFH-1 or genotype 2a viruses (Jopling et al., 2005).
Thus the p3 mutation will be more useful than other miR-122
binding site mutants for studying replication of HCV JFH-1 in the
presence and in the absence of miR-122, as it is fully comple-
mentable in multiple HCV genotype.
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miR-122-dependent replication. Luciferase expression levels
observed for miR-122-independent replication were approximately
100-fold lower than for miR-122 augmented replication. In time-
course experiments to compare luciferase expression kinetics of
miR-122-dependent and -independent replication, the 100-fold
difference was apparent by one day post-electroporation (Figs. 1C
and 6). However, after Day 1, the rate of increase in luciferase
expression of miR-122-dependent and miR-122-independent repli-
cation appears similar. Thus, we suspect that miR-122 is not
essential for ongoing HCV RNA ampliﬁcation per se, but appears
to be required to establish and sustain high levels of HCV RNA
inside the cell. This is consistent with the proposed role of miR-122
in promoting HCV RNA stability and suggests that a major role of
miR-122 is to establish HCV replication at early stages in the viral
life cycle (Machlin et al., 2011; Shimakami et al., 2012a; Villanueva
et al., 2010). In addition, di-cistronic, but not mono-cistronic HCV
RNAs are capable of miR-122-independent replication. The SGR and
FGR replicons are di-cistronic constructs, with translation of the
viral genes driven by an EMCV IRES and thus unaffected by miR-
122. The HCV IRES only drives expression of the luciferase reporter
genes, separating control of the replication machinery from normal
HCV translation mechanisms. We conclude that miR-122-
independent replication relies on the presence of the EMCV IRES
and possibly different translation regulation. It remains to be
determined if full length JFH-1 is capable of miR-122-independent
replication, and whether this phenomenon is relevant to the life
cycle of HCV in infected patients. It is also unknown if di-cistronic
replicons from other HCV isolates and genotypes will also demon-
strate capacity for miR-122-independent replication; however, we
expect this may be difﬁcult to detect in systems with replication
levels lower than that of the JFH-1 isolate. However, miR-122-
independent replication of JFH-1 SGR is a useful model to study the
role of miR-122 in the life cycle of HCV in tissue culture.
Analysis of genes that inﬂuence miR-122-dependent but not
miR-122-independent replication provides a new screening tool
for the identiﬁcation of genes involved in the activity of miR-122.
In the past, Ago2 has been implicated in the mechanism of miR-
122 augmentation of HCV replication based on data showing that
Ago2 knockdown reduces HCV RNA accumulation in infected cells
(Wilson et al., 2011). However, an indirect effect of Ago2 knock-
down on HCV replication due to modulation of other miRNA
regulated pathways could not be excluded in these experiments.
In addition, conﬂicting reports of a role for Ago2 in an experiment
in which miR-122-induced augmentation of HCV RNA accumula-
tion was measured suggest caution in interpreting data generated
by using this method (Machlin et al., 2011; Wilson et al., 2011).
Thus robust methods to conﬁrm that Ago2 or other miRNA
pathway proteins play a direct role in the mechanism miR-122
augmentation of HCV RNA accumulation were lacking. Using
wild-type and p3 sub-genomic HCV replicons to analyse miR-
122-dependent and -independent HCV replication in Hep3B and
Huh7.5 cells, we have shown that Ago2 knockdown does not
affect miR-122-independent replication, verifying that the role
of Ago2 in the HCV life cycle lies in primarily in the activity of
miR-122 (Fig. 8). Examination of replication of the SGR and FGR
constructs in a miR-122-free system such as Hep3B cells will
allow us to analyze whether other components of the miRNA
pathway involved in miR-122-mediated enhancement of HCV
stability and/or replication may also act on HCV independently
of miR-122.
Ultimately, the development of a Hep3B-based cell line for
studying the HCV life cycle will be useful for the ﬁeld of HCV
research. Nearly all HCV research is carried out in Huh7-derived
cells, all of which will bear the same host genetics and polymorph-
isms, and the same or similar dysregulation of cellular pathways,potentially limiting the value of screens designed to discover virus-
host interactions. Hep3B cells have already been useful in detecting
and conﬁrming miR-122-independent viral replication, and are an
alternative cell line in which to identify or conﬁrm other virus-host
interactions.Materials and methods
Cell lines: Huh7.5 cells are a derivative cell line of Huh7 cells
and were obtained from Charles Rice (Blight et al., 2002;
Nakabayashi et al., 1982). Hep3B cells are a human hepatoma
cell line (ATCC number HB-8064) containing an integrated Hepa-
titis B genome (Aden et al., 1979; Knowles et al., 1980). HepG2
cells (ATCC number HB-8065) are also a human hepatoma cell
line (Aden et al., 1979). All cell lines were maintained as described
previously (Wilson et al., 2011).
Plasmids and viral RNA: Plasmids pSGR JFH-1 Fluc WT and pSGR
JFH-1 Fluc GND bear sub-genomic JFH-1-derived replicons with a
ﬁreﬂy luciferase reporter (Kato et al., 2005a). Plasmids pJ6/JFH-1 FL
Rluc WT and pJ6/JFH-1 FL Rluc GNN bear full-length viral sequences
derived from the J6 (structural proteins) and JFH-1 (non-structural
proteins) isolates of HCV, and a Renilla luciferase reporter (Jones et al.,
2007). Plasmids pFGR Fluc JFH-1 WT and pFGR JFH-1 Fluc GNN bear
full-genomic di-cistronic replicons of JFH-1, and a ﬁreﬂy luciferase
reporter (Wakita et al., 2005). Plasmids pSGR p3 S1-S2 Fluc WT and
pSGR p3 S1-S2 Fluc GND have C to G mutations at position 3 in the
miR-122 seed binding sites S1 and S2 in the HCV 50 UTR. The
mutations were generated within the plasmid pSGR Fluc WT by
using the QuikChange Site-Directed Mutagenesis kit (Agilent Tech-
nologies; Mississauga, ON, Canada) and the following primers: Site A:
50–ATAGGGGCGACACTGCGCCATGAATCACTG-30 and 50–CAGTGATT-
CATGGCGCAGTGTCGCCCCTAT-30. Site B: 50–CCATGAATCACTG-
CCCTGTGAGGAAC-30 and 50–GTTCCTCACAGGGCAGTGATTCATGG-30.
‘‘GNN’’ and ‘‘GND’’ mutants of each replicon bear the indicated
inactivating mutations in the viral polymerase GDD motif. To make
viral and sub-genomic RNA, all plasmid templates were linearized
with XbaI and blunt-ended with mung bean nuclease (New England
Biolabs; Pickering, ON, Canada), and then transcribed in vitro using
the MEGAScript T7 High Yield Transcription Kit (Life Technologies;
Burlington, ON, Canada) according to the accompanying protocol.
Messenger RNA was transcribed in vitro using the mMessage
mMachine T7 Kit (Life Technologies) according to the accompanying
protocol. Fireﬂy luciferase mRNA was transcribed from the Luciferase
T7 Control DNA plasmid (Promega; Nepean, ON, Canada), linearized
using XmnI, while Renilla luciferase mRNA was transcribed from the
pRL-TK plasmid (Promega), linearized using BglII. pFluc1222 is a
plasmid coding for ﬁreﬂy luciferase followed by two repeats of the
HCV miR-122 binding sites in the 30 UTR of the reporter’s mRNA
(Machlin et al., 2011).
MicroRNAs and anti-miR sequences: miR-122: UGGAGUGUGA-
CAAUGGUGUUUGU and miR-122*: AAACGCCAUUAUCACACUAAAUA,
annealed. miR-122/p3: UGCAGUGUGACAAUGGUGUUUGU annealed
to miR-122*. miControl: UAAUCACAGACAAUGGUGUUUGU annealed
to miR-122*. The miRIDIAN microRNA Hairpin Inhibitor, human
hsa-miR-122a (proprietary sequence) was used to inhibit miR-122
(a-miR-122), with miRIDIAN microRNA Hairpin Inhibitor Negative
Control #1 (proprietary sequence) was used as a control (a-Control).
siControl: AAGACACUGAGACACCAAUUGAC (Wilson et al., 2003).
siAgo2: CAGACUCCCGUGUGUCCUATT (Wilson et al., 2011). All short
RNAs were synthesized by ThermoScientiﬁc Dharmacon (Lafayette,
CO, USA).
Electroporations: All electroporations were carried out accord-
ing to Lohmann et al. (2001) with some modiﬁcations: each
sample contained 6.0106 cells in 400 mL Dulbecco’s PBS for
electroporation, cells were plated in culture media, and 500 mL of
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electroporated using 4 mm cuvettes at inﬁnite resistance; opti-
mized for the BioRad GenePulser XCell (BioRad; Missisauga, ON,
Canada), Hep3B cells were electroporated at 225 V and 950 uF,
while Huh7.5 cells were electroporated at 270 V and 950 uF.
Where indicated, samples were electroporated with 10 mg viral
RNA; 60 pmoles microRNA and/or miR-122 antagonist; and 2 mg
messenger RNA coding for the luciferase reporter not found in the
viral replicon. In dilution experiments, the indicated amount of
microRNA was used instead. For Ago2 knockdown experiments,
8.0106 cells in 400 mL of Dulbecco’s PBS were ﬁrst electropo-
rated with 60 pmoles of the indicated siRNA to create Ago2
knockdown cells; two samples were pooled and plated in 15 cm
dishes to recover. Three days post-ﬁrst-electroporation, cells were
again prepared as above (8.0106 cells in 400 mL), and electro-
porated with 60 pmoles of the same siRNA, plus viral RNA,
microRNA, and mRNA as above. Cells were harvested at the
indicated time points and indicated as time post-second electro-
poration. For 15-day experiments, cells were passaged 1/3 on Day
9 post-electroporation due to conﬂuence.
Transfections: For miR-122 suppression activity assays, Hep3B
cells were electroporated with the indicated miRNA/miR-122
antagonist, and were plated in triplicate at 2.5105 cells per
well in 24-well dishes. Two days post-electroporation, each
sample was transfected with 50 ng pRL-TK control plasmid and
50 ng pFluc1222 in 1 mL Lipofectamine 2000 according to
the suggested protocol (Life Technologies). Cell extracts were
harvested and analyzed for luciferase expression one day post-
transfection, to analyze miR-122 suppression activity. For miR-
122 transfection to supplement cells prior to HCV infection,
Hep3B cells were plated at 1.0105 cells per well in 6-well
dishes one day before transfection. Cells were transfected accord-
ing to the Lipofectamine 2000 protocol with 100 pmol microRNA
one day prior to infection.
Infections: To evaluate HCV infectious titers, naive Huh7.5 cells
were plated at 1.0105 cells per well in a 6-well dish one day pre-
infection. Hep3B supernatant was collected at the indicated time,
spun to pellet cell debris, and 2 mL was plated on naive Huh7.5
cells. Cell extracts were harvested as above three days post-
infection and assayed for luciferase expression to monitor HCV
infection. To evaluate Hep3B infectibility, HCV infectious super-
natant from Huh7.5 cells (described below, approximately
104 FFU/mL) was plated on Hep3B cells at the indicated time
post-Hep3B-electroporation. Supernatant (2 mL) was added to
approximately 1105 Hep3B cells per well of a 6-well dish. Cell
extracts were harvested at the indicated time points post-infection
to detect infection of Hep3B cells by using luciferase assays.
HCV titration: HCV titer was evaluated by focus-forming assay.
One day pre-infection, naive Huh7.5 cells were plated on a
chamber slide such that they would be 90% conﬂuent in four
days. Cells were infected on Day 0, and ﬁxed with acetone three
days post-infection. 1:200 mouse-anti-HCV Core (C7-50, Abcam;
Cambridge, MA, USA) in 5% BSA was used to detect foci of
infection, and 1:100 goat-anti-mouse IgG Alexa-ﬂuor 488 (Life
Technologies) in PBS was used for visualization. Results are
reported as focus-forming units per mL of supernatant.
Luciferase assays: For replication assays, 500 mL electroporated
cells were plated with 4 mL media in a 6 cm dish and incubated
for 1–5 days, and cell extracts were harvested in 100 mL of the
appropriate lysis buffer. For suppression assays, cells were plated
as indicated for transfection, and were harvested in 100 mL passive
lysis buffer. The Dual Luciferase Assay Reporter Kit (Promega) was
used for all samples analyzed for both Renilla and ﬁreﬂy luciferase
activity. The Renilla Luciferase Assay Reporter System (Promega)
was used for all samples analyzed solely for Renilla luciferase
activity, and the Luciferase Assay System (Promega) was used forall samples analyzed solely for ﬁreﬂy luciferase activity. Harvests
and assays were carried out according to the kits’ protocols;
results were read in the GLOMAX luminometer (Promega) with a
2-second delay and 10-second reading.
Total RNA: Total RNA was harvested and isolated using Trizol
reagent (Life Technologies) and the associated protocol. Untreated
cells were plated at 107–108 cells per 10 cm tissue culture dish
and were harvested into 1 mL Trizol at least 24 h later. Total RNA
samples collected after HCV RNA electroporation were plated at
1.5106 cells (2 mL) on a 10 cm dish and harvested 3 days post-
electroporation into 1 mL Trizol.
qRT-PCR: miRNA qRT-PCR: miRNAs were reverse-transcribed
using the TaqMan MicroRNA Reverse Transcription Kit (Life Tech-
nologies) according to the provided protocol, with RT primers from
the hsa-miR-122 (002245) and RNU6B (001093) TaqMan MicroRNA
Assay kits (Life Technologies). miRNA qPCR reactions were
assembled according to the TaqMan Small RNA Assay protocol with
2X TaqMan Master Mix (Life Technologies) and probes for hsa-miR-
122 and RNU6B TaqMan MicroRNA Assay kits described above.
Quantitative ampliﬁcation was carried out with samples in tripli-
cate in a 96-well plate in the CFX96 real-time PCR system (BioRad)
according to kit protocol. Ago2 qRT-PCR: total cellular RNA was
reverse-transcribed using the iScript cDNA Synthesis Kit (BioRad).
qPCR reactions were carried out using the TaqMan kits
Hs00293044_m1 (Ago2) and FAM-MGB 4352934-0803022
(GAPDH); samples were ampliﬁed in triplicate as for miRNA qPCR.
All data was analyzed with the CFX Manager Software (BioRad).
Northern blot: Protocol was carried out as described in Wilson
et al. (2011). Bands were imaged and quantiﬁed using a Molecular
Imager (BioRad) and the QuantityOne software (BioRad).
Relative cell numbers: 20 mL of cells immediately post-
electroporation were plated in triplicate in a 96-well plate. Three
days post-electroporation, WST-1 reagent (Roche Diagnostics;
Laval, QC, Canada) was added to the cells according to the
manufacturer’s protocol. Colourimetric reactions based on mito-
chondrial activity were measured one to two h post-treatment on
a SpectraMax 340 PC384 Microplate Spectrophotometer (Sunny-
vale, CA, USA). Cell numbers were based on a standard curve of
ten-fold dilutions of the appropriate cell type.
Data analysis: All data are displayed as a mean of three or more
independent experiments (except where indicated) and bars
indicate standard error of the mean.Acknowledgments
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